PPARδ agonist comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-06-16. Numbers and descriptions here follow the published literature rather than marketing material.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
| Property | Value | Notes |
|---|---|---|
| Molecular target | PPAR delta (NR1C2) | Ligand-activated nuclear receptor. |
| Primary tissues studied | Skeletal muscle, liver, adipose | Effects on fatty acid oxidation and energy use. |
| Typical detection matrix | Urine | Used in anti-doping analysis. |
| Common analytical method | LC-MS/MS | Detects parent compound and metabolites. |
| Sport regulatory class | Prohibited at all times | Listed as a metabolic modulator by WADA. |
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
== History == Patellamide A was first isolated in 1981 from the tunicate L. patella collected from the reefs of Korror Island, Palau Islands. L. patella has been a rich source of peptide natural products. Aside from the patellamides, the lissoclinamides, ulicyclamide, ulithiacyclamide and ascidiacyclamide were all isolated from L. patella. The absolute stereochemistry was later determined by X-ray crystallography.
For example, it was shown that the reaction of oganesson with F2 to form the compound OgF2 would release an energy of 106 kcal/mol of which about 46 kcal/mol come from these interactions. For comparison, the spin–orbit interaction for the similar molecule RnF2 is about 10 kcal/mol out of a formation energy of 49 kcal/mol. The same interaction stabilizes the tetrahedral Td configuration for OgF4, as distinct from the square planar D4h one of XeF4, which RnF4 is also expected to have; this is because OgF4 is expected to have two inert electron pairs (7s and 7p1/2). As such, OgF6 is expected to be unbound, continuing an expected trend in the destabilisation of the +6 oxidation state (RnF6 is likewise expected to be much less stable than XeF6). The Og–F bond will most probably be ionic rather than covalent, rendering the oganesson fluorides non-volatile. OgF2 is predicted to be partially ionic due to oganesson's high electropositivity. Oganesson is predicted to be sufficiently electropositive to form an Og–Cl bond with chlorine. A compound of oganesson and tennessine, OgTs4, has been predicted to be potentially stable chemically.
== Treatment eligibility == Many providers use informed consent, whereby someone seeking hormone therapy can sign a statement of informed consent and begin treatment without much gatekeeping. For other providers, eligibility is determined using major diagnostic tools such as ICD-11 or the Diagnostic and Statistical Manual of Mental Disorders (DSM) to classify a patient with gender dysphoria. The Endocrine Society requires physicians that diagnose gender dysphoria and gender incongruence to be trained in psychiatric disorders with competency in ICD-11 and DSM-5. The healthcare provider should also obtain a thorough assessment of the patient's mental health and identify potential psychosocial factors that can affect therapy.
The two substrates of this enzyme are 2-dehydro-D-gluconic acid and oxidised nicotinamide adenine dinucleotide phosphate (NADP+). Its products are 2,5-didehydro-D-gluconic acid, reduced NADPH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is 2-dehydro-D-gluconate:NADP+ 2-oxidoreductase. Other names in common use include 2,5-diketo-D-gluconate reductase, and YqhE reductase.
Sources: en.wikipedia.org
=== Olmutinib safety concerns === On September 30, 2016, Korean regulatory authorities issued a safety alert about olmutinib in which it described two cases of toxic epidermal necrolysis, one of which was fatal, and a case of Stevens–Johnson syndrome; Boeheringer announced the termination its deal with Hanmi the same day, citing that the decision came after a review of "all available clinical data" on the drug, and also referring to competing drugs. In April 2018 Hanmi was found to have violated two laws in Korea by not disclosing adverse effects of olmutinib sooner. In that month Zai said it was dropping olmutinib and a few days later Hanmi said it was terminating development of the drug.
=== Civil rights === Bhutto Zardari has repeatedly defended the rights of minorities in Pakistan. On 4 December 2012, in a statement responding to reports about the demolition of a Hindu temple in Karachi and a desecration of an Ahmadiyya graveyard in Lahore he said, "Our forefathers did not sacrifice their lives for an intolerant, extremist, sectarian, and authoritarian Pakistan. I appeal to all of you to rise up and defend Jinnah's Pakistan. My party and I will stand by you, shoulder to shoulder." During a cake cutting ceremony for Christmas in Karachi, on 25 December 2018, Bhutto Zardari said that he PPP is the custodian of social justice, parity, religious, and interfaith harmony in the country and its advocacy for the prevalence of peace and tranquility across the world is heavily established. At the memorial for the 7th death anniversary of former Federal Minister of Interfaith Harmony, Shahbaz Bhatti on 3 March 2018, Bhutto Zardari said, "May I take this opportunity to say that we share the concerns over the misuse of blasphemy laws. This is the concern of not only the Christian community but of all of us. It is my concern too. These laws have been used as a tool by extremists to settle personal scores. They have been used to grab the properties of Christians and other non-Muslims. The blasphemy laws carry the mandatory death penalty. We must prevent their misuse. We will." On 29 September 2019, he visited the Hindus in Ghotki and the Sacho Satram Dham temple which was desecrated in the 2019 Ghotki riots and condemned the attack.
The Telecom Regulatory Authority of India (TRAI) regulates all major aspects pertaining to media and telecommunications in Jammu and Kashmir. In addition, the Jammu and Kashmir administration released their media policy in 2020 which enabled government officers to sanction journalists and media organisations for disseminating "fake news", and is valid for the next five years. The policy attracted criticism for allegedly reducing people to "passive recipients of the information the government intends to disseminate." The Press Council of India (PCI) expressed concern over the provisions of fake news in the policy, as it "interferes with the free functioning of the press." Major periodicals in Jammu and Kashmir include Greater Kashmir, Rising Kashmir, Kashmir Times, Daily Excelsior, Elite Kashmir and Kashmir Monitor. DD Kashir is the state-owned television broadcaster. Popular private television channels are ETV Urdu and Gulistan News. In association with All India Radio, DD Kashir has established high power transmitters along the India–Pakistan border. Radio Sharda, a worldwide community radio service for Kashmiri Pandits, was started by Ramesh Hangloo. FM Tadka 95.0, BIG FM 92.7, Radio Mirchi and Red FM 93.5 are private FM radio stations. Internet shutdowns are frequent in Jammu and Kashmir. As of February 2021, the region had 300 internet shutdowns since 2012. In 2020 alone, this number was 115, the highest of any year.
By 2011, CRE was reported in at least 22 countries. Between 2009 and 2012, 10 cases of CRE infections were documented in ICU patients in a Melbourne, Australia, hospital. Some cases of CRE are associated with receipt of medical care in the US. Strains found in Israel had genetic similarity to strains from the US. Hospital handwashing stations were found to be environmental reservoirs for CRE after screening all wet-area locations, including sinks, water fountains, and ice machines. The main reservoirs for CRE were the ICU sinks, and inappropriate cleaning methods accounted for transmission from sink to sink. The CRE strains in the sinks and the strains infecting the ICU patients were identical per genetic analysis. At-risk patients were being infected in the hospital setting. A study, conducted in 2016–2017 at a pediatric hospital in Kathmandu, Nepal, detected the presence of the blaNDM-1 gene among carbapenem-resistant Escherichia coli and Klebsiella pneumoniae isolates confirmed by the Modified Hodge Test, analyzing 1503 clinical samples collected over six months. Genetic analysis revealed that half of the E. coli and two-thirds of the K. pneumoniae carbapenemase-producing isolates carried the blaNDM-1 gene, highlighting the prevalence of this resistance mechanism in Nepal
France's defeat led to the rise of Britain as the world's foremost naval and economic power, a status it would hold for the remainder of the century. After the end of the Napoleonic Wars, the Congress of Vienna redrew Europe's borders and brought a relative peace to the continent, with no major great power conflicts until the Crimean War in 1853.
Sources: en.wikipedia.org
It binds to and activates PPAR delta, a nuclear receptor that controls expression of genes related to fatty acid oxidation. This mechanism can alter energy metabolism in animal models. It is not a direct stimulant or fat-burning enzyme.
Early-stage trials examined lipid and glucose markers, but the development program was discontinued. Published human results are limited and do not support approved use for any indication. Claims of performance or health benefits remain unproven.
Yes. Laboratories use LC-MS/MS to detect GW501516 and its metabolites in urine. Detection depends on timing and sensitivity, but the substance is banned at all times.
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.